BNP Paribas Financial Markets Sells 14,003 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

BNP Paribas Financial Markets reduced its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 43.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,075 shares of the biotechnology company’s stock after selling 14,003 shares during the period. BNP Paribas Financial Markets’ holdings in Aurinia Pharmaceuticals were worth $162,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $25,000. Tower Research Capital LLC TRC increased its stake in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the last quarter. Natixis acquired a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth about $49,000. Blue Trust Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at about $90,000. 36.83% of the stock is owned by institutional investors.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now owns 633,515 shares in the company, valued at $5,068,120. The trade was a 8.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at approximately $15,631,136. The trade was a 9.10% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 343,898 shares of company stock worth $2,753,094. Company insiders own 12.20% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 1.6%

Shares of Aurinia Pharmaceuticals stock opened at $7.86 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The business has a fifty day simple moving average of $7.97 and a two-hundred day simple moving average of $8.26. Aurinia Pharmaceuticals Inc. has a 1 year low of $5.15 and a 1 year high of $10.67. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -52.40 and a beta of 1.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.08 by $0.08. The business had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Research analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.